| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12603-009-0043-8 |
| P698 | PubMed publication ID | 19300880 |
| P50 | author | Henrik Zetterberg | Q6252048 |
| Kaj Blennow | Q28321550 | ||
| P2860 | cites work | Alzheimer's disease | Q29616743 |
| Core candidate neurochemical and imaging biomarkers of Alzheimer's disease | Q31162752 | ||
| Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease | Q32065439 | ||
| Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study | Q34287865 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| CSF markers for incipient Alzheimer's disease | Q35541472 | ||
| Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women | Q36227420 | ||
| CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment | Q36252166 | ||
| Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial | Q40064054 | ||
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
| Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. | Q44091581 | ||
| Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. | Q44291669 | ||
| Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. | Q45238128 | ||
| First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates | Q46317257 | ||
| CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study | Q48381623 | ||
| Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds | Q48388907 | ||
| CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease | Q48408159 | ||
| Safety and acceptability of the research lumbar puncture. | Q50951405 | ||
| Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. | Q51901649 | ||
| Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. | Q51969054 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 | ||
| Low frequency of post-lumbar puncture headache in demented patients | Q72646181 | ||
| Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice | Q73632001 | ||
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| P304 | page(s) | 358-361 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | The Journal of Nutrition, Health and Aging | Q23051112 |
| P1476 | title | Use of CSF biomarkers in Alzheimer's disease clinical trials. | |
| P478 | volume | 13 |
| Q50972636 | A quantum dot probe conjugated with aβ antibody for molecular imaging of Alzheimer's disease in a mouse model. |
| Q34679106 | Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment |
| Q53321175 | Editorial: can we improve care for patients with dementia? |
| Q28072061 | Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges |
| Q53300553 | Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease. |
| Q34228544 | Quantifying factors for the success of stratified medicine |
| Q38149355 | Risk factors for the progression of mild cognitive impairment to dementia |
| Q53300550 | Use of biomarkers in Alzheimer's trials. |
| Q37980501 | Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression |
Search more.